CN Patent

CN118924687A — 用鲁比卡丁制剂治疗小细胞肺癌的方法

Assigned to Pharmamar SA · Expires 2024-11-12 · 2y expired

What this patent protects

提供了用于通过静脉内输注施用治疗量的鲁比卡丁来治疗SCLC患者的方法。还提供了通过与其他抗癌药物，特别是拓扑异构酶抑制剂组合施用鲁比卡丁来治疗癌症的方法。本发明还涉及与止吐剂组合施用鲁比卡丁以有效控制与恶心和呕吐相关的症状、减少鲁比卡丁剂量以实现更安全的施用和增加治疗周期的数量。还提供了鲁比卡丁的稳定冻干制剂。

USPTO Abstract

提供了用于通过静脉内输注施用治疗量的鲁比卡丁来治疗SCLC患者的方法。还提供了通过与其他抗癌药物，特别是拓扑异构酶抑制剂组合施用鲁比卡丁来治疗癌症的方法。本发明还涉及与止吐剂组合施用鲁比卡丁以有效控制与恶心和呕吐相关的症状、减少鲁比卡丁剂量以实现更安全的施用和增加治疗周期的数量。还提供了鲁比卡丁的稳定冻干制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN118924687A
Jurisdiction
CN
Classification
—
Expires
2024-11-12
Drug substance claim
No
Drug product claim
No
Assignee
Pharmamar SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.